Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 3/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243641 | 1.00 | BCL2 (0.55) | BCL2ERN1CSF1RFLT1FLT3 | |
| SCHEMBL172981 | 0.88 | BCL2 (0.61) | BCL2ERN1CSF1RFLT1FLT3 | |
| SCHEMBL27352380 | 0.86 | ERN1 (0.54) | ERN1CSF1RFLT1FLT3TRPV1 | |
| SCHEMBL30504326 | 0.85 | ERN1 (0.53) | ERN1CSF1RFLT1FLT3TRPV1 | |
| SCHEMBL10243325 | 0.85 | BCL2 (0.71) | BCL2 | |
| SCHEMBL15214997 | 0.85 | BCL2 (0.57) | BCL2MGLLTDP2 | |
| SCHEMBL13756311 | 0.85 | BCL2 (0.71) | BCL2 | |
| SCHEMBL1623879 | 0.85 | BCL2 (0.57) | BCL2MGLLTDP2 | |
| SCHEMBL6999225 | 0.84 | DHODH (0.63) | ERN1CSF1RFLT1FLT3DHODH | |
| SCHEMBL28116916 | 0.83 | MAPT (0.56) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2012018868-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | BCL2 101/4885ERN1 1221/4885CSF1R 3646/4885 |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | STAT3, STAT1, STAT4 | BCL2 101/4885ERN1 1221/4885CSF1R 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.